BRPI0411131A - composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto - Google Patents
composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um compostoInfo
- Publication number
- BRPI0411131A BRPI0411131A BRPI0411131-1A BRPI0411131A BRPI0411131A BR PI0411131 A BRPI0411131 A BR PI0411131A BR PI0411131 A BRPI0411131 A BR PI0411131A BR PI0411131 A BRPI0411131 A BR PI0411131A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- obesity
- treating
- disorders
- useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 208000008589 Obesity Diseases 0.000 title abstract 5
- 235000020824 obesity Nutrition 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 3
- 102000018208 Cannabinoid Receptor Human genes 0.000 title 1
- 108050007331 Cannabinoid receptor Proteins 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 206010014612 Encephalitis viral Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002469 receptor inverse agonist Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 201000002498 viral encephalitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47785003P | 2003-06-11 | 2003-06-11 | |
| PCT/US2004/018348 WO2005000809A1 (en) | 2003-06-11 | 2004-06-09 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0411131A true BRPI0411131A (pt) | 2006-07-18 |
Family
ID=33551769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411131-1A BRPI0411131A (pt) | 2003-06-11 | 2004-06-09 | composto, método de tratar uma doença mediada pelo receptor de canabinóide 1, método de previnir a obesidade de uma pessoa com risco de obesidade, composição, e, uso de um composto |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7485732B2 (enExample) |
| EP (1) | EP1636181A1 (enExample) |
| JP (3) | JP3939744B2 (enExample) |
| KR (1) | KR20060019587A (enExample) |
| CN (1) | CN1802351A (enExample) |
| AU (1) | AU2004252109B2 (enExample) |
| BR (1) | BRPI0411131A (enExample) |
| CA (1) | CA2527933C (enExample) |
| CO (1) | CO5650244A2 (enExample) |
| EC (1) | ECSP056207A (enExample) |
| IL (1) | IL172417A0 (enExample) |
| IS (1) | IS8146A (enExample) |
| MA (1) | MA27847A1 (enExample) |
| MX (1) | MXPA05013583A (enExample) |
| NO (1) | NO20060141L (enExample) |
| NZ (1) | NZ543451A (enExample) |
| RU (1) | RU2006100298A (enExample) |
| UA (1) | UA83230C2 (enExample) |
| WO (1) | WO2005000809A1 (enExample) |
| ZA (1) | ZA200509019B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| ATE375349T1 (de) | 2002-08-02 | 2007-10-15 | Merck & Co Inc | Substituierte furo(2,3-b)pyridin derivate |
| WO2004058145A2 (en) | 2002-12-19 | 2004-07-15 | Merck & Co., Inc. | Substituted amides |
| KR20060019587A (ko) * | 2003-06-11 | 2006-03-03 | 머크 앤드 캄파니 인코포레이티드 | 치환된 3-알킬 및 3-알케닐 아제티딘 유도체 |
| US7390835B2 (en) | 2003-10-30 | 2008-06-24 | Merck & Co., Inc. | Aralkyl amines as cannabinoid receptor modulators |
| US20090306037A1 (en) * | 2005-05-02 | 2009-12-10 | Merck & Co., Inc. | Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| AR058199A1 (es) * | 2005-11-28 | 2008-01-23 | Merck & Co Inc | Derivados de 3- alquilazetidina sustituidos con heterociclos |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| PE20071092A1 (es) * | 2005-12-08 | 2007-12-10 | Aventis Pharma Inc | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico |
| EP2471810A1 (en) | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| US7999107B2 (en) | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| CA2707360A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Diphenyl substituted alkanes |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2703465A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of cb-1 antagonist/inverse agonist |
| EP2095814A1 (de) * | 2008-02-26 | 2009-09-02 | Wolfgang J. Kox | Medikamentengestützter Nikotinentzug |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| US8361959B2 (en) | 2008-10-03 | 2013-01-29 | Merck Sharp & Dohme Corp. | Spiro-imidazolone derivatives as glucagon receptor antagonists |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| MX2011004551A (es) | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida. |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| EP2440553B1 (en) | 2009-06-12 | 2017-08-23 | Merck Sharp & Dohme Corp. | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
| SG178880A1 (en) | 2009-08-26 | 2012-04-27 | Sanofi Sa | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US9682940B2 (en) | 2015-08-25 | 2017-06-20 | Janssen Pharmaceutica Nv | Indazole derivatives useful as CB-1 inverse agonists |
| JP7103950B2 (ja) | 2016-04-22 | 2022-07-20 | アクセレロン ファーマ インコーポレーテッド | Ａｌｋ７結合性タンパク質及びその使用 |
| EP3840854A4 (en) * | 2018-08-20 | 2022-06-29 | Bessor Pharma, LLC | Novel cannabinoids and cannabinoid acids and their derivatives |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
| EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| US20230365533A1 (en) | 2020-08-18 | 2023-11-16 | Merck Sharp & Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4052383A (en) | 1974-10-30 | 1977-10-04 | Schering Corporation | N-diphenylalkyl-2-benzyl azacyclic compounds |
| US4133881A (en) * | 1977-04-27 | 1979-01-09 | A. H. Robins Company, Incorporated | Azetidinyl acetonitrile and acetamide antiarrhythmia compositions and methods |
| US4242261A (en) * | 1979-07-19 | 1980-12-30 | A. H. Robins Company, Inc. | Production of methylene-cycloamines |
| JP2002511835A (ja) | 1996-06-07 | 2002-04-16 | エヌピーエス・ファーマシウティカルズ・インコーポレイテッド | 神経障害および神経病の治療に有用な受容体作動性カルシウムチャネル上の新規部位で活性な化合物 |
| EP1003514A4 (en) | 1997-07-25 | 2000-10-11 | Merck & Co Inc | CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS |
| IL141769A0 (en) | 1998-09-11 | 2002-03-10 | Aventis Pharma Sa | Azetidine derivatives, preparation and medicines containing them |
| FR2783246B1 (fr) | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
| US6635661B2 (en) | 2000-05-25 | 2003-10-21 | Sepracor Inc. | Heterocyclic analgesic compounds and methods of use thereof |
| EP1187810A2 (en) | 1999-05-25 | 2002-03-20 | Sepracor, Inc. | Heterocyclic analgesic compounds and their use |
| AU2001241927A1 (en) | 2000-02-28 | 2001-09-12 | Scios Inc. | Inhibitors of p38-alpha kinase |
| FR2805810B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
| US6479479B2 (en) | 2000-03-03 | 2002-11-12 | Aventis Pharma S.A. | Azetidine derivatives, their preparation and pharmaceutical compositions containing them |
| FR2805818B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| FR2805817B1 (fr) | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation |
| US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
| GB0019006D0 (en) | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
| FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| GB0117387D0 (en) | 2001-07-17 | 2001-09-05 | Novartis Ag | Organic compounds |
| FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
| FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
| CA2509406C (en) | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| EP1618105A1 (en) | 2003-05-01 | 2006-01-25 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders |
| AU2004234125A1 (en) | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
| KR20060019587A (ko) * | 2003-06-11 | 2006-03-03 | 머크 앤드 캄파니 인코포레이티드 | 치환된 3-알킬 및 3-알케닐 아제티딘 유도체 |
| EP1718609A1 (en) | 2004-02-17 | 2006-11-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted azetidine compounds, their preparation and use as medicaments |
| US7906652B2 (en) * | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
-
2004
- 2004-06-09 KR KR1020057023696A patent/KR20060019587A/ko not_active Ceased
- 2004-06-09 WO PCT/US2004/018348 patent/WO2005000809A1/en not_active Ceased
- 2004-06-09 EP EP04776404A patent/EP1636181A1/en not_active Withdrawn
- 2004-06-09 CA CA002527933A patent/CA2527933C/en not_active Expired - Fee Related
- 2004-06-09 BR BRPI0411131-1A patent/BRPI0411131A/pt not_active IP Right Cessation
- 2004-06-09 RU RU2006100298/04A patent/RU2006100298A/ru not_active Application Discontinuation
- 2004-06-09 US US10/557,246 patent/US7485732B2/en not_active Expired - Fee Related
- 2004-06-09 UA UAA200600239A patent/UA83230C2/ru unknown
- 2004-06-09 CN CNA2004800160109A patent/CN1802351A/zh active Pending
- 2004-06-09 JP JP2006533655A patent/JP3939744B2/ja not_active Expired - Fee Related
- 2004-06-09 NZ NZ543451A patent/NZ543451A/en unknown
- 2004-06-09 MX MXPA05013583A patent/MXPA05013583A/es unknown
- 2004-06-09 AU AU2004252109A patent/AU2004252109B2/en not_active Ceased
-
2005
- 2005-11-08 ZA ZA200509019A patent/ZA200509019B/en unknown
- 2005-11-24 IS IS8146A patent/IS8146A/is unknown
- 2005-12-05 CO CO05123378A patent/CO5650244A2/es not_active Application Discontinuation
- 2005-12-05 MA MA28634A patent/MA27847A1/fr unknown
- 2005-12-06 IL IL172417A patent/IL172417A0/en unknown
- 2005-12-08 EC EC2005006207A patent/ECSP056207A/es unknown
-
2006
- 2006-01-10 NO NO20060141A patent/NO20060141L/no not_active Application Discontinuation
-
2007
- 2007-02-13 JP JP2007031781A patent/JP2007186518A/ja active Pending
-
2008
- 2008-10-21 US US12/288,518 patent/US7906503B2/en not_active Expired - Fee Related
-
2011
- 2011-03-11 JP JP2011053759A patent/JP2011144196A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP056207A (es) | 2006-04-19 |
| US7485732B2 (en) | 2009-02-03 |
| AU2004252109B2 (en) | 2010-04-08 |
| EP1636181A1 (en) | 2006-03-22 |
| CA2527933A1 (en) | 2005-01-06 |
| RU2006100298A (ru) | 2006-05-10 |
| IS8146A (is) | 2005-11-24 |
| US20060293299A1 (en) | 2006-12-28 |
| US7906503B2 (en) | 2011-03-15 |
| ZA200509019B (en) | 2006-11-29 |
| NO20060141L (no) | 2006-03-13 |
| JP2007186518A (ja) | 2007-07-26 |
| CA2527933C (en) | 2009-08-11 |
| US20090069284A1 (en) | 2009-03-12 |
| JP3939744B2 (ja) | 2007-07-04 |
| KR20060019587A (ko) | 2006-03-03 |
| NZ543451A (en) | 2008-08-29 |
| WO2005000809A1 (en) | 2005-01-06 |
| MXPA05013583A (es) | 2006-03-09 |
| UA83230C2 (ru) | 2008-06-25 |
| MA27847A1 (fr) | 2006-04-03 |
| CN1802351A (zh) | 2006-07-12 |
| CO5650244A2 (es) | 2006-06-30 |
| JP2007500246A (ja) | 2007-01-11 |
| IL172417A0 (en) | 2006-04-10 |
| JP2011144196A (ja) | 2011-07-28 |
| AU2004252109A1 (en) | 2005-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308349A (pt) | Composto, composição, e, uso de um composto | |
| DE60316829D1 (de) | Substituierte furoä2,3-büpyridin derivate | |
| EP1496838A4 (en) | SUBSTITUTED AMIDE | |
| EP1492784A4 (en) | SUBSTITUTED 2,3-DIPHENYLPYRIDINES | |
| WO2003063781A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
| WO2004029204A3 (en) | Substituted pyrimidines | |
| UA83230C2 (ru) | Замещенные производные 3-алкил- и 3-алкенилазетидинов | |
| WO2004058145A3 (en) | Substituted amides | |
| WO2003086288A3 (en) | Bicyclic amides | |
| WO2005027837A3 (en) | Substituted sulfonamides | |
| ATE452890T1 (de) | Substituierte naphthyridinonderivate | |
| ATE501151T1 (de) | Substituierte pyrano ä2, 3 - büpyridinderivate als cannabinoid-1 rezeptormodulatoren | |
| WO2008024284A3 (en) | Sulfonylated piperazines as cannabinoid-1 receptor modulators | |
| WO2003007887A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| NO20063381L (no) | CB1 modulatorforbindelser | |
| WO2007136607A3 (en) | Substituted esters as cannabinoid-1 receptor modulators | |
| HUP0101587A2 (hu) | Antagonista vegyületek CD11/CD18 adhéziós receptor közvetítette betegségek kezelésére | |
| ECSP088477A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| CR9389A (es) | Compuestos de imidazopiridazina | |
| MY146388A (en) | Thiazole pyrazolopyrimidines as crfi receptor antagonists | |
| WO2007064566A3 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| WO2006041797A3 (en) | Acyclic hydrazides as cannabinoid receptor modulators | |
| DE602006013040D1 (de) | Substituierte pyradinon-derivate als alpha2-adrenorezeptor-antagonisten | |
| DOP2004001060A (es) | Compuestos moduladores de cb1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |